Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LXRX
- CUSIP: 52887210
- Web: www.lexpharma.com
Capitalization:- Market Cap: $1.31 billion
- Outstanding Shares: 105,581,000
Average Prices:- 50 Day Moving Avg: $14.41
- 200 Day Moving Avg: $15.27
- 52 Week Range: $11.80 - $19.62
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.47
- P/E Growth: -0.16
Sales & Book Value:- Annual Revenue: $81.1 million
- Price / Sales: 16.13
- Book Value: $1.01 per share
- Price / Book: 12.27
Profitability:- EBIDTA: ($140,120,000.00)
- Net Margins: -170.63%
- Return on Equity: -94.87%
- Return on Assets: -31.59%
Debt:- Debt-to-Equity Ratio: 0.80%
- Current Ratio: 1.86%
- Quick Ratio: 1.85%
Misc:- Average Volume: 689,338 shs.
- Beta: 0.26
- Short Ratio: 31.12
Frequently Asked Questions for Lexicon Pharmaceuticals (NASDAQ:LXRX)
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.12. The company had revenue of $12 million for the quarter, compared to analyst estimates of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business's revenue was down 40.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
When will Lexicon Pharmaceuticals make its next earnings announcement?
Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2017?
4 analysts have issued 12-month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $21.00 to $39.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $28.75 in the next year. View Analyst Ratings for Lexicon Pharmaceuticals.
What are analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. Cowen and Company analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
- 2. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/18/2017)
- 3. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
- 4. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ultragenyx Pharmaceutical (RARE), Array BioPharma (ARRY), NovoCure Limited (NVCR), Aerie Pharmaceuticals (AERI), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), MyoKardia (MYOK), Acceleron Pharma (XLRN), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), Acorda Therapeutics (ACOR) and Dermira (DERM).
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Raymond Debbane, Independent Chairman of the Board
- Lonnel Coats, President, Chief Executive Officer, Director
- Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
- Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer
- Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations
- Alexander A. Santini, Executive Vice President, Chief Commercial Officer
- Praveen Tyle Ph.D., Executive Vice President - Research and Development
- James F. Tessmer, Vice President - Finance & Accounting
- Philippe J. Amouyal, Independent Director
- Samuel L. Barker Ph.D., Independent Director
Who owns Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (54.48%), FMR LLC (14.95%), Ulys L.L.C. (4.09%), Vanguard Group Inc. (3.51%), USS Investment Management Ltd (3.32%) and Eagle Asset Management Inc. (2.71%). Company insiders that own Lexicon Pharmaceuticals stock include James F Tessmer, Lonnel Coats and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Teachers Retirement System of The State of Kentucky, Alliancebernstein L.P., GSA Capital Partners LLP, Virginia Retirement Systems ET AL, TIAA CREF Investment Management LLC, Bank of Montreal Can and Bank of New York Mellon Corp. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Pinnacle Associates Ltd., State Street Corp, Voya Investment Management LLC, DekaBank Deutsche Girozentrale, Quantitative Investment Management LLC, FMR LLC and OxFORD Asset Management LLP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Lonnel Coats and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy Lexicon Pharmaceuticals stock?
Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $12.39.
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $28.75 (132.04% upside) |
Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/17/2017 | Needham & Company LLC | Reiterated Rating | Buy | $21.00 | Medium |  |
| 8/7/2017 | Wedbush | Reiterated Rating | Ourperform | $39.00 | Low | |
| 8/1/2017 | Cowen and Company | Reiterated Rating | Hold | | High | |
| 5/3/2017 | HC Wainwright | Set Price Target | Buy | $27.00 | High | |
| 3/7/2017 | Citigroup Inc. | Boost Price Target | Buy | $24.00 -> $28.00 | N/A | |
| 8/5/2016 | Stifel Nicolaus | Boost Price Target | Buy | $25.00 -> $26.00 | N/A | |
| 5/5/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $16.00 | N/A | |
| 9/28/2015 | Gabelli | Upgrade | Sell -> Hold | $13.50 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)Earnings History by Quarter for Lexicon Pharmaceuticals (NASDAQ LXRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | ($0.36) | | | | | N/A | |
| 8/1/2017 | Q2 2017 | ($0.45) | ($0.33) | $18.34 million | $12.00 million | View | Listen | |
| 3/3/2017 | Q4 2016 | ($0.51) | ($0.31) | $15.56 million | $23.00 million | View | N/A | |
| 11/1/2016 | Q316 | ($0.50) | ($0.35) | $9.68 million | $27.70 million | View | N/A | |
| 8/4/2016 | Q216 | ($0.40) | ($0.37) | $12.36 million | $20.10 million | View | N/A | |
| 5/3/2016 | Q1 | ($0.30) | ($0.34) | $11.11 million | $12.50 million | View | N/A | |
| 3/1/2016 | Q415 | ($0.38) | $0.76 | $21.50 million | $127.30 million | View | N/A | |
| 11/6/2015 | Q3 | ($0.36) | ($0.34) | $0.44 million | $0.57 million | View | N/A | |
| 8/7/2015 | Q215 | ($0.32) | ($0.27) | $0.45 million | $376.00 million | View | N/A | |
| 4/29/2015 | Q115 | ($0.04) | ($0.04) | $1.10 million | $1.78 million | View | N/A | |
| 11/4/2014 | Q3 | ($0.05) | ($0.05) | $0.16 million | $0.40 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.05) | ($0.05) | $0.13 million | $0.68 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.05) | ($0.06) | $0.12 million | $277.00 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.06) | ($0.03) | $1.66 million | $1.40 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.01) | ($0.06) | $1.59 million | $0.24 million | View | Listen | |
| 2/21/2013 | Q4 2012 | ($0.05) | ($0.05) | $0.37 million | $0.22 million | View | N/A | |
| 11/6/2012 | Q312 | ($0.06) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)2017 EPS Consensus Estimate: ($1.70)
2018 EPS Consensus Estimate: ($1.18)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q2 2017 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q3 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q4 2017 | 1 | ($0.46) | ($0.46) | ($0.46) |
| Q1 2018 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q2 2018 | 1 | ($0.41) | ($0.41) | ($0.41) |
| Q3 2018 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q4 2018 | 1 | ($0.20) | ($0.20) | ($0.20) |
(Data provided by Zacks Investment Research)
Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lexicon Pharmaceuticals (NASDAQ:LXRX)Insider Ownership Percentage: 5.77%
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/15/2017 | Lonnel Coats | Insider | Buy | 30,000 | $12.54 | $376,200.00 | |
| 9/15/2017 | Sam L Barker | Director | Buy | 1,000 | $12.50 | $12,500.00 | |
| 6/6/2016 | James F Tessmer | VP | Sell | 1,500 | $15.00 | $22,500.00 | |
| 5/23/2016 | James F Tessmer | VP | Sell | 6,000 | $13.00 | $78,000.00 | |
| 12/12/2014 | C.V. Invus | Director | Buy | 150,000 | $0.88 | $132,000.00 | |
| 12/10/2014 | C.V. Invus | Director | Buy | 315,896 | $0.90 | $284,306.40 | |
| 11/26/2014 | International S.C.A. Artal | Director | Buy | 149,253,731 | $1.01 | $150,746,268.31 | |
| 10/23/2012 | International S.C.A. Artal | Director | Buy | 3,000,000 | $2.25 | $6,750,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Quarterly Sales of $33.98 Million
www.americanbankingnews.com - September 21 at 5:12 AM |
 | Lexicon Pharma (LXRX) Granted European Commission Approval for XERMELO (Telotristat Ethyl) - StreetInsider.com
www.streetinsider.com - September 20 at 5:40 AM |
 | Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $376200 of Shares - Nasdaq
www.nasdaq.com - September 20 at 5:40 AM |
 | European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
finance.yahoo.com - September 20 at 5:40 AM |
| Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - September 19 at 4:26 PM |
| Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 8:07 PM |
| Lonnel Coats Buys 30,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock
www.americanbankingnews.com - September 18 at 7:23 AM |
| Lexicon Pharmaceuticals, Inc. (LXRX) Director Sam L. Barker Buys 1,000 Shares
www.americanbankingnews.com - September 18 at 7:23 AM |
| Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:48 AM |
 | Lexicon Thumped Despite Favorable Data - Seeking Alpha
seekingalpha.com - September 16 at 6:14 AM |
| Slashing Fair Value Estimate on Lexicon Pharmaceuticals
finance.yahoo.com - September 16 at 6:13 AM |
 | Why Lexicon Pharmaceuticals Is Down 11% Today
www.fool.com - September 14 at 12:46 PM |
| Lexicon Pharmaceuticals is Now Oversold (LXRX)
www.nasdaq.com - September 14 at 7:24 AM |
| New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
finance.yahoo.com - September 13 at 6:19 AM |
| Lexicon Pharma (LXRX) Announces Four Data Presentations at ESMO - StreetInsider.com
www.streetinsider.com - September 9 at 5:56 AM |
| Lexicon Pharma (LXRX) Announces Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 ... - StreetInsider.com
www.streetinsider.com - September 9 at 5:56 AM |
| Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin
finance.yahoo.com - September 9 at 5:56 AM |
| Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
finance.yahoo.com - September 8 at 2:36 AM |
| Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
finance.yahoo.com - September 8 at 2:36 AM |
| Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
finance.yahoo.com - September 5 at 4:18 PM |
| Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 4:32 AM |
| Lexicon Pharmaceuticals: Stock Out Of Favor But Fundamentals Improving - Seeking Alpha
seekingalpha.com - August 27 at 7:26 PM |
| Notable Monday Option Activity: LXRX, NFLX, PRLB
www.nasdaq.com - August 21 at 7:44 PM |
| See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
finance.yahoo.com - August 18 at 6:32 AM |
| Lexicon Pharma (LXRX) Reports Additional Positive Data From ... - StreetInsider.com
www.streetinsider.com - August 16 at 5:58 AM |
| Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
finance.yahoo.com - August 16 at 5:58 AM |
| -$0.32 EPS Expected for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) This Quarter
www.americanbankingnews.com - August 13 at 4:16 PM |
| Lexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 11 at 10:56 AM |
| Equities Analysts Set Expectations for Lexicon Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:LXRX)
www.americanbankingnews.com - August 9 at 8:52 AM |
| Oversold Conditions For Lexicon Pharmaceuticals (LXRX) - Nasdaq ... - Nasdaq
www.nasdaq.com - August 9 at 3:49 AM |
| FY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:LXRX)
www.americanbankingnews.com - August 8 at 1:06 PM |
| Wedbush Reaffirms Ourperform Rating for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
www.americanbankingnews.com - August 7 at 11:20 AM |
| Lexicon Likely Stuck For A Little While - Seeking Alpha
seekingalpha.com - August 5 at 2:14 AM |
| Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 4 at 1:03 AM |
| Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
finance.yahoo.com - August 3 at 3:55 AM |
| Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : August 1, 2017
finance.yahoo.com - August 3 at 3:55 AM |
| Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 2, 2017
finance.yahoo.com - August 3 at 3:55 AM |
| Edited Transcript of LXRX earnings conference call or presentation 1-Aug-17 12:00pm GMT
finance.yahoo.com - August 3 at 3:55 AM |
 | Lexicon Pharmaceuticals Announces Opt-In Decision For US Co-Promotion Of Sotagliflozin With Sanofi In Type 1 ... - PR Newswire (press release)
www.prnewswire.com - August 2 at 3:29 AM |
| Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Hold Rating from Cowen and Company
www.americanbankingnews.com - August 1 at 2:08 PM |
| Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Posts Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - August 1 at 10:47 AM |
| Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes
finance.yahoo.com - July 31 at 7:59 PM |
| $17.60 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - July 28 at 4:57 PM |
| Comparing Intec Pharma (NTEC) & Lexicon Pharmaceuticals (LXRX)
www.americanbankingnews.com - July 28 at 12:33 PM |
| Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to Announce -$0.45 EPS
www.americanbankingnews.com - July 26 at 12:40 PM |
| Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1 ... - PR Newswire (press release)
www.prnewswire.com - July 24 at 12:40 PM |
| Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017
finance.yahoo.com - July 24 at 12:40 PM |
| Lexicon Pharma (LXRX) in Collaboration with Ipsen Granted ... - StreetInsider.com
www.streetinsider.com - July 22 at 6:17 AM |
| Lexicon Pharma (LXRX) in Collaboration with Ipsen Granted ... - StreetInsider.com
www.streetinsider.com - July 22 at 6:17 AM |
| Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)
finance.yahoo.com - July 22 at 6:17 AM |
Lexicon Pharmaceuticals (LXRX) Chart for Friday, September, 22, 2017
